Krishna Institute of Medical Sciences (KIMS) has announced the approval of its unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025. The board also approved increasing the investment limit in its material subsidiary, Sarvejana Healthcare Private Limited, by an additional ₹100 Crore. These decisions were made during the board meeting held on February 6, 2026.
Q3 Financial Results Approved
The Board of Directors has approved the unaudited standalone and consolidated financial results for the third quarter (Q3) and nine months period, ending on December 31, 2025. The results, along with the unmodified Limited Review Reports, were reviewed by the Audit Committee. Key highlights from the consolidated results include:
Consolidated Financial Performance
Total Income: ₹10,029 million for the quarter ended December 31, 2025, compared to ₹7,902 million for the quarter ended December 31, 2024.
Profit after Tax: ₹519 million for the quarter, compared to ₹720 million for the same quarter last year.
Total Comprehensive Income: ₹519 million for the quarter.
Standalone Financial Performance
Total Income: ₹4,562 million for the quarter ended December 31, 2025, compared to ₹3,681 million for the quarter ended December 31, 2024.
Profit after Tax: ₹725 million for the quarter, compared to ₹635 million for the same quarter last year.
Total Comprehensive Income: ₹725 million for the quarter.
Sarvejana Healthcare Acquisition Limit Increased
The Board has approved an increase in the investment limit for acquiring shares in Sarvejana Healthcare Private Limited (Sunshine Hospital), a material subsidiary. The limit has been increased by ₹100 Crore, to be executed in one or more tranches.
Sarvejana Healthcare Details
Sarvejana Healthcare’s total paid up equity share capital is ₹365,160,900, and the turnover for the financial year ending March 31, 2025, was ₹597.00 Cr. This strategic move aims to further enhance KIMS’ shareholding in its subsidiary.
Source: BSE
